Impact of donor HLA status on overall mortality in a cohort of T-cell-replete transplant recipients
Donor/recipient CMV serostatus . | Mortality for matched related donors (hazard ratio, 95% CI) . | Mortality for mismatched related or unrelated donors (hazard ratio, 95% CI) . |
|---|---|---|
| D-/R- | 1.0 (reference) | 1.0 (reference) |
| D+/R- | 0.98 (0.70-1.38) | 1.36 (1.06-1.74) |
| D-/R+ | 0.90 (0.65-1.24) | 1.29 (1.04-1.60) |
| D+/R+ | 1.07 (0.81-1.42) | 1.26 (1.01-1.58) |
Donor/recipient CMV serostatus . | Mortality for matched related donors (hazard ratio, 95% CI) . | Mortality for mismatched related or unrelated donors (hazard ratio, 95% CI) . |
|---|---|---|
| D-/R- | 1.0 (reference) | 1.0 (reference) |
| D+/R- | 0.98 (0.70-1.38) | 1.36 (1.06-1.74) |
| D-/R+ | 0.90 (0.65-1.24) | 1.29 (1.04-1.60) |
| D+/R+ | 1.07 (0.81-1.42) | 1.26 (1.01-1.58) |
Data from cohort previously published by Nichols et al.4 Shown are results of multivariable models, which controlled for patient/donor age, underlying disease and disease risk, conditioning regimen, cell source, GVHD prophylaxis, cell dose, and year of transplantation. Recipients of HLA-mismatched transplants from relatives and unrelated donors had similar outcomes (data not shown). For matched related donors, N = 749; for mismatched related or unrelated donors, N = 1001.